Articles On Opthea (ASX:OPT)

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Opthea (ASX:OPT) has announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.

Clinical stage biopharmaceutical company  Opthea (ASX:OPT) has received a $6.6 million research and development tax credit from the Australian Taxation Office.

The ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader index which is down by 0.30%. Two ASX-listed companies will be presenting at the annual H.C. Wainwright BIOCONNECT Virtual Conference, to be h...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

27 Oct 2021 - Opthea (ASX:OPT) has been granted a Chinese patent covering its lead compound OPT-302.

Wall Street touches record highs All three US stock benchmark indexes rose again overnight, as the Dow and the S&P500 reached new all-time highs in intraday trade. The Dow closed 0.04% higher, while the S&P 500 was up by 0.18%, and...

Opthea (OPT) opens patient enrolment for its Phase 3 clinical program for the treatment of wet age-related macular degeneration in the Asia-Pacific region OPT says the clinical trial sites build upon the progress of other international reg...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing, compared to the broader index which is higher by 1%. Truscreen Group (ASX:TRU) was the best health stock performer, up by 38% after reporting key milestones including the...

Wall Street continues recent bull run All three US indices rallied again overnight, with oil prices and Bitcoin also surging to recent highs. The Dow Jones lifted 0.56%, the S&P 500 by 0.74%, and tech heavy Nasdaq by 0.71%. Solid earnin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is tumbling lower. At the time of writing, the benchmark index is down 0.75% to 7,224.5 points. Four ASX shares that are falling more than most to...

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Opthea (ASX:OPT) has announced that enrollment in its pivotal Phase 3 clinical program of OPT-302 for the treatment of wet age-related macular degeneration is now open in Europe.

Tech stocks drag Wall Street lower A selloff in technology stocks dragged Wall Street sharply lower overnight, amid concerns of higher inflation. All three US stock market benchmarks fell – with the Dow Jones dropping by 0.94%, the S&P...

Looking for some small cap shares to add to your watchlist? Then have a look at the ones listed below. Here’s why they could be worth getting better acquainted with: Bigtincan Holdings Ltd (ASX: BTH) The first small cap to watch is Bigti...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Clinical stage biopharmaceutical company Opthea (ASX:OPT) has announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration....

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 7,319.9 points. Four ASX shares that have failed to follow the market higher today are...

In early afternoon trade on Tuesday, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is sinking. At the time of writing, the benchmark index is down 0.3% to 7,294.9 points. Four ASX shares that are not letting tha...

The Opthea Ltd (ASX: OPT) share price is soaring today, up more than 8% trading at $1.37 at the time of writing. The clinical stage biopharmaceutical company is focused on developing therapies to treat progressive retinal diseases. Below,...

Immutep (ASX:IMM) and Opthea (ASX:OPT) both received the blessing of the FDA for their clinical trial ambitions this morning, with Immutep winning approval to start a clinical trial and Opthea winning Fast Track Designation.   Opthea gets F...

Opthea (ASX:OPT) has announced that the US FDA has granted Fast Track designation for its OPT-302 in combination with anti-VEGFA therapy for the treatment of patients with neovascular age-related macular degeneration.

Didi ban and Kaseya ransom Wall Street was closed on Monday due to the extended Independence Day long weekend. Chinese regulators ordered app stores in China to block ride-hailing Didi app from being downloaded, just less than a week after...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and trading lower. At the time of writing, the benchmark index is down 0.3% to 7,363.5 points. Four ASX shares that are not letting that hold them back are liste...

The best performer on the All Ordinaries on Thursday has been the Opthea Ltd (ASX: OPT) share price. In morning trade, the biotechnology company’s shares are up 12% to $1.58. Why is the Opthea share price rocketing higher? Investors have b...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were broadly positive about the announcement. However, some industry...

Goldman Sachs hosted its 4th small/mid-cap healthcare forum this week. This included 13 Australian and New Zealand healthcare companies across a diverse range of specialties. Here are the ASX healthcare shares that Goldman picked as a buy....

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been granted a meeting with the US Food and Drug Administration to discuss the planned development pathway for its lead drug Presendin in the treatment of disorders...

Source: PHICHCHA, Shutterstock Small-cap stocks can be surprising investments as they can offer high revenues within a short span of time. These stocks might not be the most expensive ones. However, they can gain significant value over tim...

Pitt Street Research has initiated coverage on Melbourne biotech company Exopharm (ASX:EX1), declaring it is currently significantly undervalued and could be re-rated by the market. In a 29-page research report, Pitt Street Research lauded...

Source:Ratanapon Srisuneton, Shutterstock Summary Opthea gets an iPSP waiver from the FDA for its lead product candidate to treat wet AMD. Paradigm and bene pharmaChem set to collaborate for the development of iPPS and other formulati...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.6% to 6,845.9 points. Four ASX shares that are climbing more than most today are liste...

The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.  Opthea is committed to impro...

Wall Street pulls back as tech stocks retreat All the major US indices fell last night. Dow Jones was down slightly by 0.3%, while S&P 500 and NASDAQ fell by 0.32% and 0.11% respectively. Tech stocks like Apple, Microsoft, Amazon, and F...